Kymera Therapeutics director Pamela Esposito executed a pair of equity moves on March 20, 2026, selling common stock and simultaneously exercising options tied to the same issuer.
In a series of sales on that date, Esposito sold 2,500 shares of Kymera Therapeutics (NASDAQ: KYMR) common stock for a combined value of $197,877. The transactions settled at weighted average prices within a band of $77.7111 to $79.9442 per share. On the same day she exercised options to acquire 2,500 shares at an exercise price of $49.10, representing a total expenditure of $122,750 for the option exercise.
After completing the sales and the option exercise, Esposito directly owns 0 shares of Kymera Therapeutics. The timing of the sale is notable against the backdrop of the stock’s strong performance over the last year; the share price has risen roughly 135% during that period. Separately, InvestingPro analysis cited in relation to the stock indicates the shares may be overvalued at current levels.
Corporate and clinical developments at Kymera are advancing in parallel. The company has scheduled presentation of data from its KT-621 BroADen Phase 1b trial in patients with atopic dermatitis for the American Academy of Dermatology 2026 Annual Meeting. That presentation is set for March 28, 2026, in Denver, Colorado.
Investor sentiment from the sell-side has shifted higher following the company’s fourth-quarter and full-year 2025 financial results. Stephens raised its price target to $100 while maintaining an Overweight rating. Morgan Stanley adjusted its target to $123 and also stayed with an Overweight rating, citing progress in Kymera’s degrader pipeline and market opportunities in type 2 diseases. RBC Capital increased its price target to $108 while maintaining an Outperform rating and highlighted that phase II development of KT-621 in both atopic dermatitis and asthma is underway, with readouts expected in 2027.
These analyst updates, the upcoming data presentation and the director-level transactions together underscore ongoing market attention on Kymera’s clinical progress and valuation. The company’s pipeline milestones and external analyst reassessments are likely to remain focal points for investors monitoring KYMR in the near term.